Click here to get full coverage on Here's Why Lantern Pharma (NASDAQ:LTRN) Must Use Its Cash Wisely - simplywall.st

Here's Why Lantern Pharma (NASDAQ:LTRN) Must Use Its Cash Wisely  simplywall.st

Here's Why Lantern Pharma (NASDAQ:LTRN) Must Use Its Cash Wisely - simplywall.st

Click here to get full coverage on Lantern Pharma (NASDAQ: LTRN) posts LP-184 Phase 1a data, eyes biomarker-guided Phase 1b/2 - Stock Titan

Lantern Pharma (NASDAQ: LTRN) posts LP-184 Phase 1a data, eyes biomarker-guided Phase 1b/2  Stock Titan

Lantern Pharma (NASDAQ: LTRN) posts LP-184 Phase 1a data, eyes biomarker-guided Phase 1b/2 - Stock Titan

Click here to get full coverage on Lantern Pharma (NASDAQ:LTRN) Will Have To Spend Its Cash Wisely - Yahoo Finance

Lantern Pharma (NASDAQ:LTRN) Will Have To Spend Its Cash Wisely  Yahoo Finance

Lantern Pharma (NASDAQ:LTRN) Will Have To Spend Its Cash Wisely - Yahoo Finance

Click here to get full coverage on $LTRN stock is up 11% today. Here's what we see in our data. - Quiver Quantitative

$LTRN stock is up 11% today. Here's what we see in our data.  Quiver Quantitative

$LTRN stock is up 11% today. Here's what we see in our data. - Quiver Quantitative

Click here to get full coverage on Enlivex Therapeutics and Lantern Pharma Interviews to Air on the RedChip Small Stocks, Big Money(TM) Show on Bloomberg TV - Daily Commercial

Enlivex Therapeutics and Lantern Pharma Interviews to Air on the RedChip Small Stocks, Big Money(TM) Show on Bloomberg TV  Daily Commercial

Enlivex Therapeutics and Lantern Pharma Interviews to Air on the RedChip Small Stocks, Big Money(TM) Show on Bloomberg TV - Daily Commercial

Click here to get full coverage on Lantern Pharma (NASDAQ: LTRN) CEO Discusses AI-Driven Cancer Drug Development in FintechTV Interview at NYSE - The Globe and Mail

Lantern Pharma (NASDAQ: LTRN) CEO Discusses AI-Driven Cancer Drug Development in FintechTV Interview at NYSE  The Globe and Mail

Lantern Pharma (NASDAQ: LTRN) CEO Discusses AI-Driven Cancer Drug Development in FintechTV Interview at NYSE - The Globe and Mail

Click here to get full coverage on Lantern Pharma stock climbs after LP-184 cancer drug hits trial endpoints - Investing.com

Lantern Pharma stock climbs after LP-184 cancer drug hits trial endpoints  Investing.com

Lantern Pharma stock climbs after LP-184 cancer drug hits trial endpoints - Investing.com

Click here to get full coverage on Lantern Pharma advances AI-Driven cancer drug after successful Phase 1a trial - Proactive financial news

Lantern Pharma advances AI-Driven cancer drug after successful Phase 1a trial  Proactive financial news

Lantern Pharma advances AI-Driven cancer drug after successful Phase 1a trial - Proactive financial news

Click here to get full coverage on Lantern Pharma Engages New to The Street for National Media Coverage Featuring Television, Press, Earned Media and Non-Deal Investor Focused Roadshows - Abilene Reporter-News

Lantern Pharma Engages New to The Street for National Media Coverage Featuring Television, Press, Earned Media and Non-Deal Investor Focused Roadshows  Abilene Reporter-News

Lantern Pharma Engages New to The Street for National Media Coverage Featuring Television, Press, Earned Media and Non-Deal Investor Focused Roadshows - Abilene Reporter-News

Click here to get full coverage on Lantern Pharma Engages New to The Street for National Media Coverage Featuring Television, Press, Earned Media and Non-Deal Investor Focused Roadshows - Victorville Daily Press

Lantern Pharma Engages New to The Street for National Media Coverage Featuring Television, Press, Earned Media and Non-Deal Investor Focused Roadshows  Victorville Daily Press

Lantern Pharma Engages New to The Street for National Media Coverage Featuring Television, Press, Earned Media and Non-Deal Investor Focused Roadshows - Victorville Daily Press

Click here to get full coverage on Lantern Pharma (LTRN) Reports Promising Phase 1 Trial Results fo - GuruFocus

Lantern Pharma (LTRN) Reports Promising Phase 1 Trial Results fo  GuruFocus

Lantern Pharma (LTRN) Reports Promising Phase 1 Trial Results fo - GuruFocus

Click here to get full coverage on $LTRN stock is up 12% today. Here's what we see in our data. - Quiver Quantitative

$LTRN stock is up 12% today. Here's what we see in our data.  Quiver Quantitative

$LTRN stock is up 12% today. Here's what we see in our data. - Quiver Quantitative

Click here to get full coverage on Here's Why We're Watching Lantern Pharma's (NASDAQ:LTRN) Cash Burn Situation - Yahoo Finance

Here's Why We're Watching Lantern Pharma's (NASDAQ:LTRN) Cash Burn Situation  Yahoo Finance

Here's Why We're Watching Lantern Pharma's (NASDAQ:LTRN) Cash Burn Situation - Yahoo Finance

Click here to get full coverage on Lantern Pharma (NASDAQ: LTRN) Reports Q3 2025 Results and Highlights AI-Driven Clinical Progress - The Globe and Mail

Lantern Pharma (NASDAQ: LTRN) Reports Q3 2025 Results and Highlights AI-Driven Clinical Progress  The Globe and Mail

Lantern Pharma (NASDAQ: LTRN) Reports Q3 2025 Results and Highlights AI-Driven Clinical Progress - The Globe and Mail

Click here to get full coverage on LTRN - Lantern Pharma Inc Latest Stock News & Market Updates - Stock Titan

LTRN - Lantern Pharma Inc Latest Stock News & Market Updates  Stock Titan

LTRN - Lantern Pharma Inc Latest Stock News & Market Updates - Stock Titan

Click here to get full coverage on Lantern Pharma Inc. (LTRN): AI-Driven Cancer Drug Development - Yahoo Finance

Lantern Pharma Inc. (LTRN): AI-Driven Cancer Drug Development  Yahoo Finance

Lantern Pharma Inc. (LTRN): AI-Driven Cancer Drug Development - Yahoo Finance

Click here to get full coverage on Breakthrough: Advanced Lung Cancer Patient Achieves Complete Response After 3 Failed Therapies - Stock Titan

Breakthrough: Advanced Lung Cancer Patient Achieves Complete Response After 3 Failed Therapies  Stock Titan

Breakthrough: Advanced Lung Cancer Patient Achieves Complete Response After 3 Failed Therapies - Stock Titan

Click here to get full coverage on Lantern Pharma (NASDAQ: LTRN) CEO Panna Sharma Featured on IBN’s BioMedWire Podcast - The Globe and Mail

Lantern Pharma (NASDAQ: LTRN) CEO Panna Sharma Featured on IBN’s BioMedWire Podcast  The Globe and Mail

Lantern Pharma (NASDAQ: LTRN) CEO Panna Sharma Featured on IBN’s BioMedWire Podcast - The Globe and Mail

Click here to get full coverage on Lantern Pharma (LTRN) Secures EU Patent for Cancer Drug LP-284 - GuruFocus

Lantern Pharma (LTRN) Secures EU Patent for Cancer Drug LP-284  GuruFocus

Lantern Pharma (LTRN) Secures EU Patent for Cancer Drug LP-284 - GuruFocus

Click here to get full coverage on Is Lantern Pharma (NASDAQ:LTRN) In A Good Position To Invest In Growth? - Yahoo Finance

Is Lantern Pharma (NASDAQ:LTRN) In A Good Position To Invest In Growth?  Yahoo Finance

Is Lantern Pharma (NASDAQ:LTRN) In A Good Position To Invest In Growth? - Yahoo Finance

Click here to get full coverage on Lantern Pharma Inc. (LTRN): A Penny Stock That Will Make You a Millionaire - Yahoo Finance

Lantern Pharma Inc. (LTRN): A Penny Stock That Will Make You a Millionaire  Yahoo Finance

Lantern Pharma Inc. (LTRN): A Penny Stock That Will Make You a Millionaire - Yahoo Finance

Click here to get full coverage on Lantern Pharma’s Promising Phase II Lung Cancer Study: Key Insights for Investors - TipRanks

Lantern Pharma’s Promising Phase II Lung Cancer Study: Key Insights for Investors  TipRanks

Lantern Pharma’s Promising Phase II Lung Cancer Study: Key Insights for Investors - TipRanks

Click here to get full coverage on Lantern Pharma’s LP-284 Study: A Potential Game-Changer in Cancer Treatment? - TipRanks

Lantern Pharma’s LP-284 Study: A Potential Game-Changer in Cancer Treatment?  TipRanks

Lantern Pharma’s LP-284 Study: A Potential Game-Changer in Cancer Treatment? - TipRanks

Click here to get full coverage on Lantern Pharma shareholders elect directors and approve stock option repricing - Investing.com

Lantern Pharma shareholders elect directors and approve stock option repricing  Investing.com

Lantern Pharma shareholders elect directors and approve stock option repricing - Investing.com

Click here to get full coverage on Lantern Pharma (LTRN) Stock Forecast and Price Target 2025 - MarketBeat

Lantern Pharma (LTRN) Stock Forecast and Price Target 2025  MarketBeat

Lantern Pharma (LTRN) Stock Forecast and Price Target 2025 - MarketBeat

Click here to get full coverage on Lantern Pharma Secures FDA Clearance for Planned Phase 1b/2 Trial of LP-184 in Biomarker-Defined, Treatment-Resistant NSCLC Patients with High Unmet Clinical Need - Yahoo Finance

Lantern Pharma Secures FDA Clearance for Planned Phase 1b/2 Trial of LP-184 in Biomarker-Defined, Treatment-Resistant NSCLC Patients with High Unmet Clinical Need  Yahoo Finance

Lantern Pharma Secures FDA Clearance for Planned Phase 1b/2 Trial of LP-184 in Biomarker-Defined, Treatment-Resistant NSCLC Patients with High Unmet Clinical Need - Yahoo Finance

Click here to get full coverage on Lantern Pharma Reports Complete Response in Heavily Pre-Treated Lymphoma Patient with LP-284 in Phase 1 Clinical Trial - Business Wire

Lantern Pharma Reports Complete Response in Heavily Pre-Treated Lymphoma Patient with LP-284 in Phase 1 Clinical Trial  Business Wire

Lantern Pharma Reports Complete Response in Heavily Pre-Treated Lymphoma Patient with LP-284 in Phase 1 Clinical Trial - Business Wire

Click here to get full coverage on Lantern Pharma to Present AI-Driven Cancer Drug Development & Research Platforms at Inaugural AI for Biology and Medicine Symposium at UNT - Yahoo Finance

Lantern Pharma to Present AI-Driven Cancer Drug Development & Research Platforms at Inaugural AI for Biology and Medicine Symposium at UNT  Yahoo Finance

Lantern Pharma to Present AI-Driven Cancer Drug Development & Research Platforms at Inaugural AI for Biology and Medicine Symposium at UNT - Yahoo Finance

Click here to get full coverage on Lantern Pharma Completes Targeted Enrollment for Lung Cancer Phase 2 Harmonic™ Clinical Trial in Japan for LP-300 - BioSpace

Lantern Pharma Completes Targeted Enrollment for Lung Cancer Phase 2 Harmonic™ Clinical Trial in Japan for LP-300  BioSpace

Lantern Pharma Completes Targeted Enrollment for Lung Cancer Phase 2 Harmonic™ Clinical Trial in Japan for LP-300 - BioSpace

Click here to get full coverage on Lantern Pharma and Actuate Therapeutics Announce Research & Development Collaboration Leveraging Lantern's Artificial Intelligence Platform - PR Newswire

Lantern Pharma and Actuate Therapeutics Announce Research & Development Collaboration Leveraging Lantern's Artificial Intelligence Platform  PR Newswire

Lantern Pharma and Actuate Therapeutics Announce Research & Development Collaboration Leveraging Lantern's Artificial Intelligence Platform - PR Newswire

Click here to get full coverage on Lantern Pharma Reports Second Quarter 2025 Financial Results and Business Updates - Business Wire

Lantern Pharma Reports Second Quarter 2025 Financial Results and Business Updates  Business Wire

Lantern Pharma Reports Second Quarter 2025 Financial Results and Business Updates - Business Wire

Click here to get full coverage on LTRN Stock Price and Chart — NASDAQ:LTRN - TradingView — Track All Markets

LTRN Stock Price and Chart — NASDAQ:LTRN  TradingView — Track All Markets

LTRN Stock Price and Chart — NASDAQ:LTRN - TradingView — Track All Markets

Click here to get full coverage on Lantern Pharma Announces Significant Positive Preclinical Data in Pancreatic Cancer With Drug Candidate LP-184 - PR Newswire

Lantern Pharma Announces Significant Positive Preclinical Data in Pancreatic Cancer With Drug Candidate LP-184  PR Newswire

Lantern Pharma Announces Significant Positive Preclinical Data in Pancreatic Cancer With Drug Candidate LP-184 - PR Newswire

Click here to get full coverage on The 3 Best Machine Learning Stocks to Quadruple Your Money by 2035 - InvestorPlace

The 3 Best Machine Learning Stocks to Quadruple Your Money by 2035  InvestorPlace

The 3 Best Machine Learning Stocks to Quadruple Your Money by 2035 - InvestorPlace

Click here to get full coverage on 3 AI Stocks You’ll Regret Not Buying Soon - InvestorPlace

3 AI Stocks You’ll Regret Not Buying Soon  InvestorPlace

3 AI Stocks You’ll Regret Not Buying Soon - InvestorPlace

Click here to get full coverage on The 3 Most Undervalued AI Penny Stocks to Buy in December - InvestorPlace

The 3 Most Undervalued AI Penny Stocks to Buy in December  InvestorPlace

The 3 Most Undervalued AI Penny Stocks to Buy in December - InvestorPlace

Click here to get full coverage on LTRN: Lantern Calls On Califia for Antibody Drug Conjugates - Yahoo Finance

LTRN: Lantern Calls On Califia for Antibody Drug Conjugates  Yahoo Finance

LTRN: Lantern Calls On Califia for Antibody Drug Conjugates - Yahoo Finance

Click here to get full coverage on Lantern Pharma (LTRN) Stock Price, News & Analysis - MarketBeat

Lantern Pharma (LTRN) Stock Price, News & Analysis  MarketBeat

Lantern Pharma (LTRN) Stock Price, News & Analysis - MarketBeat

Click here to get full coverage on Starlight Therapeutics, a Subsidiary of Lantern Pharma Focused on CNS & Brain Cancers, Announces Dr. Marc Chamberlain as Chief Medical Officer - Business Wire

Starlight Therapeutics, a Subsidiary of Lantern Pharma Focused on CNS & Brain Cancers, Announces Dr. Marc Chamberlain as Chief Medical Officer  Business Wire

Starlight Therapeutics, a Subsidiary of Lantern Pharma Focused on CNS & Brain Cancers, Announces Dr. Marc Chamberlain as Chief Medical Officer - Business Wire

Click here to get full coverage on 7 AI Penny Stocks That Could Skyrocket in 2023 - InvestorPlace

7 AI Penny Stocks That Could Skyrocket in 2023  InvestorPlace

7 AI Penny Stocks That Could Skyrocket in 2023 - InvestorPlace

Click here to get full coverage on 10 Best Artificial Intelligence Stocks Under $10 - Yahoo Finance

10 Best Artificial Intelligence Stocks Under $10  Yahoo Finance

10 Best Artificial Intelligence Stocks Under $10 - Yahoo Finance

Click here to get full coverage on Lantern Pharma Advances Pediatric Brain Cancer Treatment Using AI Platform - citybuzz

Lantern Pharma Advances Pediatric Brain Cancer Treatment Using AI Platform  citybuzz

LTRN

Price Chart

Key Statistics

Technicals

About LTRN

Latest News

Here's Why Lantern Pharma (NASDAQ:LTRN) Must Use Its Cash Wisely - simplywall.st

Lantern Pharma (NASDAQ: LTRN) posts LP-184 Phase 1a data, eyes biomarker-guided Phase 1b/2 - Stock Titan

Lantern Pharma (NASDAQ:LTRN) Will Have To Spend Its Cash Wisely - Yahoo Finance

Advanced Charts

Top Gainers

Top Losers